FDA's Decisions in Oncology Drug Product Approvals from 2006 to 2016

Conclusion The overall results of this research validated the attitude of the FDA toward applying each expedited program to facilitate an earlier delivery of innovative oncology drug products to patients with cancer.
Source: Health Policy and Technology - Category: Health Management Source Type: research